Oral vs Injectable — How Delivery Works
There are now two FDA-approved oral GLP-1 pills for weight loss — the Wegovy pill (oral semaglutide, December 2025) and Foundayo (orforglipron, April 2026) with no food restrictions. Here is how oral and injectable delivery differ, and why oral options took so long to develop.
Quick read · 5 min
Current approved options at a glance
*Average from clinical trials — individual results vary
The Wegovy pill (semaglutide 25mg, once daily) was FDA approved December 22, 2025, and launched in the US in January 2026. In clinical trials, participants lost an average of ~16.6% body weight with full adherence, at dramatically lower cost (~$149/month vs ~$1,350/month).
See semaglutide page for full details →Why oral GLP-1s are challenging
GLP-1 drugs like semaglutide and liraglutide are peptides — chains of amino acids, essentially small proteins. The digestive system is designed to break down proteins. When you swallow a peptide:
- ✕Stomach acid immediately begins denaturing (unfolding) the peptide structure
- ✕Pepsin (a stomach enzyme) starts cleaving the peptide chain
- ✕Even if it reaches the small intestine, intestinal enzymes further degrade it
- ✕What remains is largely amino acids — not an intact drug molecule
This is why subcutaneous injection has been the standard — it delivers the drug directly under the skin into the lymphatic system and bloodstream, bypassing the digestive system entirely. Subcutaneous semaglutide has approximately 42% bioavailability.
Solution 1: SNAC technology (oral semaglutide)
Oral semaglutide (Rybelsus) uses a chemical called SNAC (Sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) to sneak the drug through the stomach wall. SNAC works through three mechanisms:
- 1pH buffering: SNAC locally raises the pH around the tablet, reducing pepsin activity — the enzyme that would otherwise destroy semaglutide.
- 2Monomerisation: Changes local polarity so semaglutide molecules stay separate (monomeric) rather than clumping — making them easier to absorb across the stomach lining.
- 3Membrane permeabilisation: SNAC embeds temporarily into stomach lining cells, making them more permeable to semaglutide molecules.
Bioavailability caveat: Oral semaglutide achieves less than 1% bioavailability vs ~42% for subcutaneous. A much higher dose is required orally (14mg tablet vs 2.4mg injection) to achieve comparable effect. It must be taken on an empty stomach with no more than 120ml (4oz) of water, at least 30 minutes before food.
Solution 2: Small molecule oral GLP-1s (Foundayo / orforglipron)
Foundayo (orforglipron, Eli Lilly, FDA approved April 2026) takes a fundamentally different approach. Unlike oral Wegovy — which uses SNAC technology and requires a fasting window — Foundayo has no food or water restrictions at all. Rather than a peptide, it is a small molecule — a different class of drug entirely.
- •Protein structure — destroyed by stomach acid
- •Requires SNAC technology or injection
- •Strict food timing restrictions (oral)
- •Low oral bioavailability (<1%)
- •Naturally acid-stable — gut-resistant
- •No special technology needed
- •No food timing restrictions
- •Higher oral bioavailability
In a large clinical trial (3,127 adults with obesity), participants taking Foundayo lost an average of 12.4% body weight at 72 weeks — comparable to injectable GLP-1s at similar timepoints. It is the first oral GLP-1 drug with no food or water timing restrictions.
The oral GLP-1 landscape in 2026
As of April 2026, there are two FDA-approved oral GLP-1 drugs for weight loss — plus one in late development:
The key trade-off between the two approved oral options is weight loss vs convenience. Oral Wegovy produces more weight loss but requires strict morning fasting. Foundayo produces somewhat less weight loss but can be taken any time with no restrictions.
Common questions
Next step most people take
Based on clinical trials · No rankings · Every claim linked to source
Last reviewed: April 2026